FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

UNIB APPRO	JVAL
OMB Number:	3235-0287
Estimated average burd	en
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Rivera Jose E (Last) (First) (Middle) C/O INTELLIA THERAPEUTICS, INC. 40 ERIE STREET; SUITE 130 (Street) CAMBRIDGE MA 02139					3. C 11/	Issuer Name and Ticker or Trading Symbol Intellia Therapeutics, Inc. [NTLA] Date of Earliest Transaction (Month/Day/Year) 11/04/2020 4. If Amendment, Date of Original Filed (Month/Day/Year)								S. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) EVP, General Counsel 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting					
(City)	(St	ate)	(Zip)											Perso	n				
		Tab	le I - No	on-Deriv	ative	Sec	uriti	ies Ac	quired	l, Dis	sposed o	of, or Be	neficia	lly Owned	 t				
Date			2. Transa Date (Month/D		Execution Date,		3. 4. Securities Acc Transaction Code (Instr. 8) 4. Securities Acc Disposed Of (D) 5)				Securities Beneficia	5. Amount of Securities Beneficially Owned Following		nership Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
								Code	v	Amount	(A) or (D)	Price	Transacti (Instr. 3 a	on(s)			(111501. 4)		
Common Stock 11			11/04/	2020				M		5,000	A	\$13.8	45,6	45,679		D			
Common Stock			11/04/	/2020				S ⁽¹⁾		3,364	D	\$28	42,3	42,315		D			
Common Stock													262,	210 I		I	See Footnote ⁽		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
Derivative Conversion Date Execution Date, T Security or Exercise (Month/Day/Year) if any C				ransaction of ode (Instr. Derivative		Expiration Date (Month/Day/Year) So			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownersh Form: Direct (D or Indire (I) (Instr.	Benefic Owners ct (Instr. 4)				
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares						
Stock Option (right to	\$13.88	11/04/2020			М			5,000	(3)		01/05/2027	Common Stock	5,000	\$0.00	110,0	000	D		

Explanation of Responses:

- 1. The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- 2. Shares are held by Rivak Capital LLC ("Rivak"). Mr. Rivera is a member and the general manager of Rivak and has voting and dispositive power over these shares.
- 3. The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 107,812 shares as of November 4, 2020.

Remarks:

<u>/s/Jose Rivera</u>

** Signature of Reporting Person Date

11/06/2020

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.